A prime-boost vaccination strategy using a Semliki Forest virus replicon vectored DNA vaccine followed by a recombinant adenovirus protects pigs from classical swine fever.
- Author:
Yuan SUN
1
;
Dafei LIU
;
Yufei WANG
;
Na LI
;
Hongyu LI
;
Bingbing LIANG
;
Huaji QIU
Author Information
1. Division of Swine Infectious Diseases, State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150001, China.
- Publication Type:Journal Article
- MeSH:
Adenoviridae;
genetics;
metabolism;
Adenovirus E2 Proteins;
genetics;
immunology;
Animals;
Classical Swine Fever;
immunology;
prevention & control;
Classical swine fever virus;
genetics;
immunology;
Genetic Vectors;
Immunization, Secondary;
Replicon;
genetics;
Semliki forest virus;
genetics;
metabolism;
Swine;
Vaccines, DNA;
immunology;
Viral Envelope Proteins;
genetics;
metabolism;
Viral Vaccines;
immunology
- From:
Chinese Journal of Biotechnology
2009;25(5):679-685
- CountryChina
- Language:Chinese
-
Abstract:
We have previously evaluated a Semliki Forest virus (SFV) replicon vectored DNA vaccine (pSFV1CS2-E2) and a recombinant adenovirus (rAdV-E2) expressing the E2 glycoprotein of classical swine fever virus (CSFV) in pigs. The results showed that the immunized pigs were protected from virulent challenge, but few pigs showed short-term fever and occasional pathological changes following virulent challenge. To enhance the immunogenecity of the vaccines, we tried a prime-boost vaccination strategy using a combination of prime with pSFV1CS2-E2 followed by boost with rAdV-E2. The results showed that all the immunized pigs developed high-level CSFV-specific antibodies following prime-boost immunization. When challenged with virulent CSFV, the immunized pigs (n = 5) from the heterologous boost group showed no clinical symptoms, and CSFV RNA was not detected following challenge, whereas one of five pigs from the homologous boost group developed short-term fever and CSFV RNA was detected. This demonstrates that the heterologous prime-boost vaccination regime has the potential to prevent against virulent challenge.
